Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products in clinical development include ibrutinib (PCI-32765), which is initiating Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; co-operative research and development agreement with National Cancer Institute to develop ibrutinib; and license agreement with the University of Texas to develop and commercialize porphyrins, expanded porphyrins, and other porphyrin-like substances. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.